17 In VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy; NCT04349072), mavacamten significantly reduced the eligibility for invasive SRT after 16 or 32 weeks of treatment among patients with oHCM who met guide...